Trofinetide
- Generic Name
- Trofinetide
- Brand Names
- Daybue
- Drug Type
- Small Molecule
- Chemical Formula
- C13H21N3O6
- CAS Number
- 853400-76-7
- Unique Ingredient Identifier
- Z2ME8F52QL
Overview
Trofinetide is a novel synthetic analog of glypromate, also known as glycine–proline–glutamate (GPE), a naturally occurring protein in the brain and the N-terminal tripeptide of insulin-like growth factor 1 (IGF-1). Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome, which is an X-linked neurodevelopmental disorder characterized by a range of cognitive, motor, and autonomic symptoms. Trofinetide is believed to work by reducing inflammation and apoptosis of neurons.
Background
Trofinetide is a novel synthetic analog of glypromate, also known as glycine–proline–glutamate (GPE), a naturally occurring protein in the brain and the N-terminal tripeptide of insulin-like growth factor 1 (IGF-1). Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome, which is an X-linked neurodevelopmental disorder characterized by a range of cognitive, motor, and autonomic symptoms. Trofinetide is believed to work by reducing inflammation and apoptosis of neurons.
Indication
Trofinetide is indicated for the treatment of Rett syndrome in adults and pediatric patients two years of age and older.
Associated Conditions
- Rett Syndrome
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.